- Home
- App Analytics
- M3 India - Med News CME Survey
M3 India - Med News CME Survey app analytics for December 14
M3 India - Med News CME Survey
- Neuroglia Health Private Limited
- Apple App Store
- Free
- Medical
“One-stop platform for Indian Doctors”
-About M3-
M3 India app is a free and exclusive platform for Indian Doctors that helps them stay updated with practice-relevant information, while saving them time. M3 India is owned and managed by Neuroglia Health Private Limited (NHPL). Over 5mn+ Doctors across 9 countries trust M3 Group for their daily practice.
-Medical News & Journal Summaries-
Short summaries from most important Journals and Clinical news by specialty, Expert articles, General news and happenings related to Indian Doctors
-Daily Quiz-
Application based quiz based on research published in key journals. Play and compete with peers!
-Market Research-
Doctors can join our Market Research panel to take part in paid Market research studies and earn honorarium while also contributing to developments in Healthcare!
We are constantly updating the M3 India app and adding new features which are useful for our doctor members.
Store Rank
The Store Rank is based on multiple parameters set by Google and Apple.
All Categories in
United States--
Medical in
United States--
Create an account to see avg.monthly downloadsContact us
M3 India - Med News CME Survey Ranking Stats Over Time
Similarweb's Usage Rank & Apple App Store Rank for M3 India - Med News CME Survey
Rank
No Data Available
M3 India - Med News CME Survey Ranking by Country
Counties in which M3 India - Med News CME Survey has the highest ranking in its main categories
No Data to Display
Top Competitors & Alternative Apps
Apps with a high probability of being used by the same users, from the same store.
OC Academy
Omnicuris healthcare private limited
Medflix
Plexus Professionals Network Private Limited
DiabetoCompanion
Update Video Publications Private Limited
VKonnect Health
INTEGRACE PRIVATE LIMITED
M3 India - Med News CME Survey VS.
December 14, 2024